When was Transcode Therapeutics founded?

Transcode Therapeutics was founded in 2015 and raised its 1st funding round 6 years after it was founded.

Where is Transcode Therapeutics located?

Transcode Therapeutics is headquartered in Boston, United States.

Who is the current CEO of Transcode Therapeutics?

Michael Dudley of Transcode Therapeutics.

How many employees does Transcode Therapeutics have?

As of Sep 30, 2026, the latest employee count at Transcode Therapeutics is 16.

Is Transcode Therapeutics a funded company?

Transcode Therapeutics is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Apr 15, 2021.

When was the latest funding round of Transcode Therapeutics?

Transcode Therapeutics' latest funding was a $***** Grant (prize money) round on Jun 19, 2025, with participation from 1 investor.

Where does Transcode Therapeutics rank among its competitors?

Transcode Therapeutics ranks 865th amongst 3828 active competitors, of which 1298 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Transcode Therapeutics?

Transcode Therapeutics' top competitors include Jazz Pharmaceuticals, BeiGene and Alnylam. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Transcode Therapeutics - 2026 Company Profile, Team, Funding, Competitors & Financials

Transcode Therapeutics is a public company based in Boston (United States), founded in 2015 by Anna Moore and Michael Dudley. It operates as a Developer of mRNA therapeutics to treat cancer. Transcode Therapeutics has raised an undisclosed amount in funding. The company has 3828 active competitors, including 1298 funded and 879 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Alnylam.

Company Details

Developer of mRNA therapeutics to treat cancer. The company's product line include TTX-MC138 focused on treating metastatic cancer. Other drug candidates include TTX-siPDL1, TTX-siLIN28b, TTX-RIGA, TTX-CRISPR, and TTX-mRNA, focusing on treating cancer using RNA technology.

Key Metrics

Founded Year

2015

Location

Boston, United States

Stage

Public

Latest Funding Round

Grant (prize money), Jun 19, 2025, $*****

Investors

TRITON FUNDS & 3 more

Ranked

865^th among 3828 active competitors

Employee Count

16 as on Sep 30, 2026

Similar Companies

Jazz Pharmaceuticals & 3587 more

Exit Details

Public

View Transcode Therapeutics' full profile

Transcode Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
TRANSCODE THERAPEUTICS, INC. CIN: 1829635 , United States, Active	Jan 10, 2016	-	19 (As on Dec 31, 2023)	-

Transcode Therapeutics got listed on Jul 09, 2021.

Click here to take a look at Transcode Therapeutics's IPO in detail

Transcode Therapeutics has raised funding over 6 rounds. Its first funding round was on Apr 15, 2021. Its latest funding round was a Grant (prize money) round on Jun 19, 2025 for $*****. 1 investor participated in its latest round. Transcode Therapeutics has 4 institutional investors.

Here is the list of recent funding rounds of Transcode Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 19, 2025	9156968	Grant (prize money)	2419270	3135853	7146544	8270065
Nov 27, 2024	5624852	Post IPO	9485328	2849546	3134239	3501687
Sep 05, 2024	2101468	Grant (prize money)	1315321	6859917	1337514	NIH

Access funding benchmarks and valuations. Sign up today!

View details of Transcode Therapeutics's funding rounds and investors

The founders of Transcode Therapeutics are Anna Moore and Michael Dudley.

Here are the details of Transcode Therapeutics' key team members:

Anna Moore: Co-Founder of Transcode Therapeutics. They are also an angel investor in 2 startups.
Michael Dudley: Co-Founder & CEO of Transcode Therapeutics.
Contact Info: 1 email address

View details of Transcode Therapeutics's Founder profiles and Board Members

Transcode Therapeutics' employee count trend

Transcode Therapeutics has 16 employees as of Sep 26. Here is Transcode Therapeutics's employee count trend over the years:

Employee count trend for Transcode Therapeutics

Uncover Transcode Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Transcode Therapeutics include Jazz Pharmaceuticals, BeiGene and Alnylam. Here is the list of Top 10 competitors of Transcode Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, Atlas Venture & 13 others	80/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	73/100
6th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
7th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
8th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
865th	Transcode Therapeutics 2015, Boston (United States), Public	Developer of mRNA therapeutics to treat cancer	-	TRITON FUNDS, NIH & 2 others	47/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Transcode Therapeutics's competitors? Click here to see the top ones

Transcode Therapeutics has made no investments or acquisitions yet.

Here is the latest report on Transcode Therapeutics's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to Transcode Therapeutics

Media has covered Transcode Therapeutics for a total of 10 events in the last 1 year, 6 of them have been about company updates and 2 about people movement.